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Abstract
Background: Advances in the nucleic acid sequencing technologies have ushered in the era of genetic-based
“precision medicine”. Applications of the genetic discoveries to practice of medicine, however, are hindered by
phenotypic variability of the genetic variants. The report illustrates extreme pleiotropic phenotypes associated with
an established causal mutation for hereditary cardiomyopathy.
Case presentation: We report a 61-year old white female who presented with syncope and echocardiographic and
cardiac magnetic resonance (CMR) imaging findings consistent with the diagnosis of hypertrophic cardiomyopathy
(HCM). The electrocardiogram, however, showed a QRS pattern resembling an Epsilon wave, a feature of
arrhythmogenic right ventricular cardiomyopathy (ARVC). Whole exome sequencing (mean depth of coverage of exons
178X) analysis did not identify a pathogenic variant in the known HCM genes but identified an established causal
mutation for ARVC. The mutation involves a canonical splice accepter site (c.2146-1G > C) in the PKP2 gene, which
encodes plakophillin 2. Sanger sequencing confirmed the mutation. PKP2 is the most common causal gene for ARVC
but has not been implicated in HCM. Findings on echocardiography and CMR during the course of 4-year follow up
showed septal hypertrophy and a hyperdynamic left ventricle, consistent with the diagnosis of HCM. However, neither
baseline nor follow up echocardiography and CMR studies showed evidence of ARVC. The right ventricle was normal
in size, thickness, and function and there was no evidence of fibro-fatty infiltration in the myocardium.
Conclusions: The patient carries an established pathogenic mutation for ARVC and a subtle finding of ARVC but
exhibits the classic phenotype of HCM, a contrasting phenotype to ARVC. The case illustrates the need for detailed
phenotypic characterization for patients with hereditary cardiomyopathies as well as the challenges physicians face in
applying the genetic discoveries in practicing genetic-based “precision medicine”.
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Backgrounds
Technological advances in nucleic acid sequencing have
enabled identification of the genetic variants (GVs) across
the genome and have ushered in utilization of the GVs in
practice of medicine. Genetic-based “personalized medi-
cine” or “precision medicine” advocates for exploiting the
information content of the GVs to determine susceptibility
to disease, individualize therapy, in order to maximize
gain and to reduce the side effects, prognosticate, and as-
sess the clinical outcomes. In a broader definition, “preci-
sion medicine” promotes utilizing various individualized
indicators, encompassing metabolomics, transcriptomics,
genomics, proteomics, environmental exposures, and
microbiome, among others, to tailor the medical manage-
ment of an individual.
Single gene disorders, whereby the effect size of the
GVs are relatively large, are the prototypic diseases for
the applications of genetic-based “precision medicine”.
However, there is considerable phenotypic variability
and pleiotropic effects, even in single gene disorders.
The variability typically results from different mutations
in a given causal gene causing distinct phenotypes. The
point has been illustrated for hereditary cardiomyopa-
thies, whereby different mutations in genes encoding
sarcomere proteins can cause either hypertrophic cardio-
myopathy (HCM) or dilated cardiomyopathy (DCM) and
affect severity of the phenotypic expression [1–3]. How-
ever, phenotypic variability of a specific mutation associ-
ated with two distinct cardiomyopathy phenotypes is
less well appreciated. We report an interesting patient
who exhibits the classic phenotype of hypertrophic car-
diomyopathy (HCM) but carries a rare mutation that
has been established to cause the contrasting phenotype of
arrhythmogenic right ventricular cardiomyopathy (ARVC).
Case presentation
The patient is a 61-year white (European decent, non-
Finish) female who presented with unexplained syncope
4 years ago. She had no prior history of syncope, cardiac
arrhythmias, cardiovascular diseases, and no family his-
tory of cardiomyopathies. She had a past medical history
of depression and mild hypothyroidism, which have been
controlled with medical therapy. Her physical examin-
ation was unremarkable. A 12-lead ECG was notable for
possible left atrial enlargement, q waves in L1 and aVL, a
QRS morphology resembling right bundle branch block
with an epsilon wave, and non-specific ST and T changes
(Fig. 1a and b). Holter monitoring (24 h) showed a run
of 5-beat ventricular tachycardia and frequent ventricular
premature beats and couplets (Fig. 1c). An echocardiogram
showed asymmetric left ventricular hypertrophy with an
interventricular septal thickness of 19 mm (normal range:
6–11 mm), a posterior wall thickness of 1.1 cm, a hyperdy-
namic left ventricle with an ejection fraction of > 60%, a
normal right ventricular size and function, and reduced
myocardial tissue Doppler velocities (Fig. 1, d–g). She had
no overload conditions, such as systemic arterial hyperten-
sion or valvular pathology to explain cardiac hypertrophy.
The findings were consistent with the diagnosis of HCM.
She was treated with a beta-blocker for HCM, which she
soon discontinued. She was taking aspirin (81 mg/d), cho-
lecalciferol (1000 units/d), and levothyroxine (75 mg/d),
and received monthly intramuscular injection of paliperi-
done palmitate for depression.
The proband had no family history of HCM or ARVC
(Fig. 2). She was never married and had no child. Pro-
band’s mother (I-2 in the Pedigree) had atrial fibrillation
with a controlled ventricular rate at 80 bpm and left an-
terior fascicular block on a 12-lead ECG but no Epsilon
wave or evidence of cardiac hypertrophy. Individual I-2
had an echocardiogram at 80 years of age, which was
4 years prior to her death, which showed a normal left
ventricular size and function with an interventricular
wall thickness of 0.9 cm. She had no evidence of right
ventricular dilatation or dysfunction on the echocardio-
gram. Proband’s father (I-1 in the Pedigree) had a history
of coronary artery disease and died in a car accident at
an old age. Proband’s brother (II-2) had no history of
heart disease and died from septic shock and respiratory
failure, as complications of liver cirrhosis caused by
hepatitis C. Proband’s half-sister had degenerative aortic
valve disease and underwent aortic valve replacement in
her 50s.
Whole exome sequencing (WES) was performed on
the Illumina 2500 platform as part of clinical genetic
testing by a commercial company. Sequencing pro-
duced 2 × 100 bp reads, which were aligned to the
human reference genome (hg19) using BWA-Mem
(v0.7.8) [4]. The BAM files, containing the sequence
alignment data, were analyzed to identify the GVs
using Platypus (v0.8.1) [5]. CASSANDRA (v2.0) was
used to annotate the GVs [6]. The discovered variants
were filtered by minor allele frequency <1% (ExAc overall
minor allele frequency, http://exac.broadinstitute.org/)
and prioritized providing they met any of the following
criteria:
1) Stop gain, splicing (2 bp of canonical site), and
any insertion or deletion
2) Pathogenic or likely pathogenic as annotated by
ClinVar [7]
3) Nonsynonymous variants that met all the following
criteria
a. CADD_PH (combined annotation-dependent
depletion phred score) score > 10
b. Medium or high likelihood of being deleterious
as assessed by mutation assessor [8],
c. PolyPhen2:HVAR [9] score > 0.9
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The mean depth of coverage of exons in the entire
dataset was 178 times. In the entire data set, 95.3% of
the exons had at least 10 sequence reads. Further ana-
lysis of the 15 genes known to cause HCM and pheno-
copy conditions, namely MYBPC3, MYH7, TNNT2,
TNNI3, TPM1, ACTC1, MYL2, MYL3, FH11, NEXN,
PLN, GLA, LAMP2, and PRKAG2 showed 100% had at
least 10 reads and 98% had at least 20 reads (Table 1).
A total of 80 candidate GVs in the WES data, including
29 insertions/deletions, 16 variants a introducing premature
stop codon, 3 variants affecting the splicing sites, and
32 deleterious non-synonymous variants met the fil-
tering criteria (Additional file 1: Table S1). No patho-
genic variant in any of the established causal genes for
HCM was identified. Given the high read coverage
(Table 1), the possibility of missing a causal variant in
HCM genes was very low. Ten of the candidate patho-
genic variants were in genes associated with a phenotype
per Online Mendelian Inheritance in Man (OMIM) data-
base [10]. The list included CLDN16, COL6A2, COL6A3,
FANCD2, GPR179, LFNG, NOTCH3, PKP2, POF1B,
TGIF1 (Table 2).
A
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Fig. 1 Phenotypic data. a 12-lead electrocardiogram is notable for a QRS morphology resembling right bundle branch block with an epsilon
wave, a pattern similar to that observed in Brugada syndrome. b QRS morphology in lead V1 showing an Epsilon wave. c A rhythm strip from a
Holter monitoring recording showing a 5-beat non-sustained ventricular tachycardia. d A parasternal long axis echocardiographic view showing
interventricular septal hypertrophy. e Septal tissue Doppler imaging, showing reduced velocities. f and g. CMR images, fat saturation sequence f
and cardiac function g, showed a normal RV size and function and no gadolinium enhancement in the RV
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Among the pathogenic variants identified, the most
plausible pathogenic variant for the phenotype in the
proband is a rare splice variant (c.2146-1G > C) in the
PKP2 gene (NM_001005242.2), which encodes plakophilin
2 (<1 in 20,000 in ExAc database in European – Non-
Finnish population). PKP2 is the most common causal
gene for ARVC [11]. The variant is predicted to disrupt the
canonical splice acceptor site in exon 10 of the PKP2 gene
and has been reported in multiple independent probands/
families to cause ARVC [11–14]. The variant was read 183
times in the WES data and was confirmed by Sanger se-
quencing (Fig. 3). Because the c.2146-1G >C variant is
known to cause ARVC [11–14], the patient was further
evaluated for this distinct form of cardiomyopathy. The
ECG and echocardiogram were unchanged. CMR showed
interventricular septal hypertrophy but no evidence of right
ventricular dilatation, dysfunction, aneurysm, or fibro-
adipocyte infiltration (Fig. 1, panels f and g, and Additional
file 2: Movie S1 and Additional file 3: Movie S2).
Discussion
Although different mutations in a single gene can cause
distinct phenotypes, the observed association of a single
mutation with two distinct and contrasting phenotypes,
namely HCM and ARVC, is rare, if not unique. The
former is characterized by cardiac myocyte hypertrophy,
classically in the left ventricle and the latter by myocyte
atrophy, apoptosis, and excess fibro-adipocytes, classic-
ally in the right ventricle. The patient had a clear clinical
diagnosis of HCM, as evidenced by the presence of
asymmetric cardiac hypertrophy with a predominant in-
volvement of the interventricular septum, on multiple
echocardiograms and CMR, in the absence of a second-
ary cause, such as systemic arterial hypertension or aor-
tic stenosis. However, the patient did not meet the
clinical criteria for the diagnosis of ARVC, despite
Fig. 2 Pedigree. Pedigree of the proband containing the phenotypic data of the key members is shown. Square box and circle represent male
and female members respectively. Full circle indicates an affected member. The / symbol indicates a deceased individual. Age at the time of
death is shown. Abbreviations: CAD: Coronary artery disease; MVA: Motor vehicle accident; A Fib: Atrial fibrillation; LVH: left ventricular hypertrophy;
HCM: Hypertrophic cardiomyopathy; AVR: Aortic valve replacement. Age at the time of death is shown in parenthesis are shown in the figure
Table 1 Coverage of known HCM and HCM-phenocopy genes
in the WES data
Gene Proportion of coding region covered at given level
1x 10x 20x
MYBPC3 1 1 0.9663
MYH7 1 1 1
TNNT2 1 1 0.9989
TNNI3 1 1 0.8674
TPM1 1 0.9993 0.9289
ACTC1 1 1 1
MYL2 1 1 1
MYL3 1 1 1
FH11 1 1 1
NEXN 1 1 1
PLN 1 0.9983 0.9883
GLA 1 1 1
LAMP2 1 1 1
PRKAG2 1 1 0.9589
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carrying a well-established mutation in the most com-
mon causal gene for ARVC [11]. The QRS pattern re-
sembling an epsilon wave is considered a major, albeit
insufficient, diagnostic criterion for the ARVC, evoking
possible ARVC [15]. The absence of a full ARVC pheno-
type in the proband might reflect incomplete pene-
trance, which is a known feature of the PKP2 variants
[14]. The Epsilon wave observed in the proband is not a
feature of HCM but is a major diagnostic criterion for
ARVC. The electrocardiographic pattern also resembles
the pattern observed in Brugada syndrome [16], which is
also associated with the PKP2 mutations [17]. However,
cardiac hypertrophy is not a feature of the Brugada
syndrome.
The published evidence for the pathogenic role of
the c.2146-1G > C variant in ARVC is strong [11–13].
However, its causal role in HCM is uncertain. Rare vari-
ants, including the pathogenic variants, are population-
Table 2 Variants identified in the WES data whose corresponding genes have been associated with mendelian disorders
Gene containing a pathogenic variant Disease/Phenotype listed in OMIM Phenotype in the proband
CLDN16 • Hypomagnesemia Not documented
COL6A2 • Bethlem myopathy 1
• Ullrich congenital muscular dystrophy 1
• ?Myosclerosis
Not documented
COL6A3 • Bethlem myopathy 1
• Dystonia 27
• Ullrich congenital muscular dystrophy 1
Not documented
FANCD2 • Fanconi anemia Not documented
GPR179 • Night blindness, Congenital stationary (complete)
• 1E, autosomal recessive
Not documented
LFNG • ?Spondylocostal dysostosis 3\autosomal recessive Not documented
NOTCH3 • Cerebral arteriopathy with subcortical infarcts and
leukoencephalopathy 1
• Lateral meningocele syndrome
• ?Myofibromatosis, infantile 2
Not documented
PKP2 • Arrhythmogenic right ventricular cardiomyopathy Suggestive
POF1B • Premature ovarian failure 2B Not documented
TGIF1 • Holoprosencephaly 4 Not documented
A B
Fig. 3 The number of reads in WES and confirmation of the genetic variant by Sanger sequencing. a Whole exome sequencing data showing the
number of reads covering the c.2146-1G > C variant in the PKP2 gene. b Sanger sequencing showing heterozygous G > C read out, confirming the
WES data
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specific. Consequently, detection of a pathogenic variant,
previously identified as a disease-causing variant, in a
single individual is insufficient to imply causality. Indeed,
unambiguous ascertainment of genetic causality, regard-
less of the causal gene and variant, is exceedingly challen-
ging if not impossible. HCM in this patient might be
caused by undetected pathogenic variants, structural vari-
ants, and variants did not meet the filtering criteria [18].
The exome of this patient also contained a rare variant in
the OBSCN gene, which is a candidate gene for DCM but
not an established causal gene for HCM [19]. As shown in
Table 1, WES had provided an excellent coverage to 15
known HCM and HCM-phenocopy genes. Thus, it is very
unlikely that a pathogenic variant in the common HCM
gene was undetected. Finally, it is also possible that a copy
number variant or a large deletion, not detected by whole
exome sequencing, is responsible for HCM in this case,
albeit such variants are found in < 1% of HCM cases [20].
Thus, one cannot exclude concomitant presence of HCM
and ARVC phenotypes in this case.
Conclusions
The case illustrated extreme phenotypic pleiotropy associ-
ated with a PKP2 mutation, which is an established causal
mutation for ARVC and yet this pathogenic variant was
found in a patient with the well-defined contrasting
phenotype of HCM. The diversity of the phenotypic ex-
pression of GVs does not diminish the clinical utilities of
genetic testing in hereditary cardiomyopathies. To the
contrary, the findings emphasize the need for better un-
derstanding of the phenotypic variability associated with
the GVs by placing the focus on detailed phenotypic and
genetic characterization of the patient. The ambiguities in
genotype-phenotype correlation in this case illustrate the
challenges physicians face in applying the genetic discove-
ries to the practice medicine. To quote Sir William Osler,
the practice of “medicine is a science of uncertainty and
an art of probability”. It seems to remains so, even in the
era of “precision medicine”.
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